I'm going to assume the larger powers to be ,know the full potential of INO and all its worth. Now with all that potential,please tell me why ,with all that, WE are at .678 per.
On anticipation and potential sales alone, wouldn't you all think this is not the place we should be? This is what we should be talking about...why are we still here..I've been doing this for longer than I can remember,25 yrs. plus...this is my alarm bell. with that I am still long..G..
Two things are hapening here,One is sell on the news! and the other, the chart has filled its previousl gap.unless some unforseen thing has happened,this was just a tec. move
Two things are hapening here,One is sell on the news! and the other is the chart has come back to fill its gap.uless some unforseen thing has happened,
You guys need some sex in your lives,you need to drain of some of that testosterone!..There's more to life than "stevey boy"!
ME TWO!!..win 8 is a desaster in my opinion..Google IS eating breakfast,lunch and dinner at their expense..The phone..hello..
bIG BROTHER yAHOO WONT LET ME POST THE LINK..
novio Biomedical (INO) is focused on the development of multiple DNA-based vaccines through its electroporation-delivery platform. The company has shown, through multiple pre-clinical and Phase I studies, that its delivery system enhances the potency of vaccines to not only prevent but also treat both cancers and infectious diseases.
Current vaccination techniques inject either a weakened virus or protein particles from a virus into the host, with the goal of allowing the host immune system to create an antibody response to the foreign protein or virus. The issue facing our current vaccination technique is that viral strains will mutate and change, causing changes in protein expression that can make vaccines ineffective. On a yearly basis, drug companies and government agencies attempt to predict the strains of influenza viruses to create the appropriate flu vaccine. Some years the vaccines are effective, other years they are not.
Inovio's DNA vaccine design solves this problem because a killed or weakened virus is used. A strip of DNA from either a virus or a cancer cell called plasmid is created using existing genetic sequences to target either a disease (cancer) or viral infection. This DNA is a "synthetic consensus" DNA-sequenced vaccine and made in pure water to maximize safety issues. The "synthetic consensus" approach allows the vaccine to prevent and treat multiple strains of a virus expression and overcome the current barriers of viral mutation or expressions that makes today's vaccines less effective.
Single page viewpage 1 / 2| Next »
These findings, in conjunction with the results from previously conducted studies with LEAPS vaccines in the RA model of Collagen Induced arthritis (CIA) with a dominant Th17 cytokine profile, suggest that LEAPS vaccines may be used as a therapeutic treatment for different types of RA, which depend on the proteins implicated (e.g., Proteoglycan or Collagen), genetic factors, and different cytokine profiles (e.g., Th1 or Th17). LEAPS vaccines may be advantageous to other therapies because the LEAPS vaccines act early on the immune system and inhibit the production of disease-promoting inflammatory cytokines, unlike anti-Tumor necrosis factor alpha (TNFa) therapy which generally acts late and neutralizes only one individual inflammatory cytokine out of many involved in the disease process. This is a significant step forward in the development of the LEAPS technology in hopes of taking it into human studies," said Dr. Zimmerman.
RA is a chronic inflammatory disease that